Tagged with BI,

UAE Long-established as the Middle East and Africa’s leading country in terms of rapid access to biomedical innovation, the UAE is looking to bolster this positioning in the coming years. Indeed, allowing innovation to flourish – including through hosting greater numbers of clinical trials in the country and protecting intellectual property…

Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…

UAE Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time frames to their counterparts in the US and Europe, in some cases even ahead. Against this backdrop, the representatives of…

UAE Speaking exclusively to PharmaBoardroom, H.E. Dr Noura Al Ghaithi, Undersecretary of the Department of Health Abu Dhabi outlines Abu Dhabi’s rapid progression towards becoming a global life science hub, how the DoH is drawing on international collaborations to help solve the most burning healthcare issues, as well as the transformative…

UAE Ahmad Abu Dahab became the first Middle East employee for Swedish-headquartered haematology, immunology and specialty care player SOBI back in 2012 and now serves as VP for the entire Middle East, Turkey, and Northern Africa region. Abu Dahab explains some of the key trends at play in the rare diseases…

UAE Cleveland Clinic Abu Dhabi ranks as the UAE’s best hospital, in the top 150 globally, and recently opened a new comprehensive state-of-the-art cancer centre. CEO Dr Jorge A. Guzman outlines how the hospital’s focus on providing complex, quality, patient-centric care is a key differentiator, its role in raising standards of…

Germany Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19 deaths among patients using its products and other areas of the business were faced with economic headwinds, the group was…

Spain Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19 treatment, and the reimbursement challenges faced by rare disease players in Spain. Moreover, De Mora highlights Sobi’s vast clinical trials…

Saudi Arabia Khaled Harb, general manager of Saudi distributor Abdulrehman Algosaibi, highlights the changing distribution landscape in Saudi Arabia, the importance of offering comprehensive solutions that go beyond traditional services, what the updated role of procurement body NUPCO means for the industry, and shares his perspective on the Vision 2030 transformation.  …

Saudi Arabia Altibbi’s Ayman Sharaiha outlines the evolution of the company to date to become the largest digital health platform in MENA, explains how the COVID-19 pandemic has accelerated telehealth adoption, and calls for increased innovative collaboration between pharmaceutical companies, health insurance companies and digital health companies.   A major global challenge…

Germany A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines and lockdowns in the country, as well as the German pharma firms making international investments and predicting mid-term growth.   Pharma companies must deliver promised…

Belgium In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European and global ecosystem. Here we highlight some of the key themes of the discussions: innovation, generics and biosimilars, and teamwork.…